title: [Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack].
abstract: Sumatriptan has been used successfully in the acute treatment of migraine since 1991. Most patients (70-80%) experience pain relief 2-4 hours after receiving 100 mg sumatriptan orally. During last few years efficacy of lower doses has been studied. Many authors proved that 50 mg of sumatriptan may be as effective as 100 mg. Our study confirmed that 50 mg oral dose of sumatriptan is sufficient in many patients. Headache relief was achieved in 58% of treated patients after single dose. The second dose of sumatriptan was effective in next 14% of patients. Totally headache relief after two doses of sumatriptan was achieved in 72% of patients. The sumatriptan 50 mg was well tolerated; only 10% of patients reported adverse events, which were minor and transient.
authors.affiliation: Katedry i Kliniki Neurologii AM w Lodzi.
authors.forename: A
authors.initials: A
authors.lastname: Prusiński
authors.forename: F
authors.initials: F
authors.lastname: Król
mesh_terms: D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D012074:Remission Induction; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use*; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D018170:Sumatriptan
vernacular_title: Ocena skuteczności i tolerancji sumatryptanu w dawce 50 mg w leczeniu napadu migreny.